Wegovy Pen vs Compounded Vial: 12 Practical Differences Before You Switch

Brand-name Wegovy and compounded semaglutide contain the same active molecule when both are prepared correctly. But the delivery format is completely different — Wegovy ships in a pre-filled multi-dose injector pen designed for patients with no syringe experience, while compounded semaglutide ships in a sterile glass vial that the patient draws from with a separate insulin syringe at every dose. The differences matter more than people expect, and the learning curve catches new patients off-guard. This article documents 12 specific operational differences worth knowing before you decide which format is right for you.

1. The injection device itself

Wegovy pen: a pre-filled, single-use, single-dose injector that comes ready to use. The patient removes a cap, presses the pen against the injection site, and clicks a button. The pen has a hidden needle that retracts after the dose is delivered. No vial, no syringe, no measuring [1, 2].

Compounded vial: a sterile glass vial containing a multi-week or multi-month supply of semaglutide solution. The patient receives separate insulin syringes (typically 0.3 mL capacity, 31-gauge needle) and draws each weekly dose individually. Vial-and-syringe is the standard delivery format for any 503A compounded injectable [3].

2. Dose precision and the math problem

Wegovy pen: each pen delivers exactly one dose. The dose tier is printed on the box (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg). Patients escalate by changing which pen they receive monthly — they never measure anything themselves [1].

Compounded vial: the patient draws each dose from the vial using markings on the insulin syringe. The dose in milligrams must be converted to volume in milliliters or units using the concentration printed on the vial label (typically 2.5 mg/mL or 5 mg/mL, but it varies by compounder). A 0.5 mg dose at 2.5 mg/mL concentration equals 0.2 mL — the patient must perform this calculation correctly every week. The FDA has received hundreds of adverse-event reports of dosing errors caused by unit-conversion mistakes when patients confused milliliters with units, or read the wrong tick mark on the syringe. This is the single biggest practical risk of the compounded format.

3. Refrigeration requirements

Wegovy pen: must be refrigerated at 36–46°F (2–8°C) until first use. Once a pen is in use, it can stay at room temperature (up to 86°F / 30°C) for up to 28 days, after which any remaining drug must be discarded [1, 2]. In practice, Wegovy single-dose pens are used immediately, so the room- temperature window is rarely relevant.

Compounded vial: typically must be refrigerated at 36–46°F (2–8°C) for the entire shelf life of the vial, which is usually 28–60 days from compounding depending on the pharmacy's validation studies. The exact in-use beyond-use date is set by the compounding pharmacy and printed on the label per USP <797> rules [3]. Patients who travel with compounded semaglutide need a small insulated cooler or a TSA-friendly travel pouch to keep the vial chilled.

4. Needle gauge and injection comfort

Wegovy pen: uses a hidden 32-gauge ultra-thin needle (0.23 mm diameter) that retracts after the injection. Patients typically rate the injection as nearly painless — the needle gauge is finer than most insulin syringes [1].

Compounded vial: patients use whichever insulin syringe their telehealth provider ships with the kit. Most ship 31-gauge syringes (0.25 mm) which are slightly thicker than Wegovy's pen needle. Some ship 30-gauge or even 29-gauge syringes, which are noticeably more painful. If you're sensitive to injection discomfort, ask your compounded provider which gauge they ship and request 31-gauge or finer if it isn't the default.

5. Injection site rotation

Both formats use the same subcutaneous injection sites: abdomen (avoiding a 2-inch zone around the navel), upper thighs, or upper arms. Both formats benefit from rotating sites to avoid lipohypertrophy (fat tissue thickening at repeatedly-injected sites). The rotation discipline is the same whether you're using a pen or a vial — site selection has nothing to do with the delivery format.

6. Travel logistics

Wegovy pen: single-dose pens are TSA-approved for carry-on with the prescription label visible. You can take a single pen on a trip in an insulated travel pouch and inject in your hotel room. The fact that the pen is one-time-use eliminates the need to bring extra syringes.

Compounded vial: you must travel with the vial itself plus enough insulin syringes for the doses you'll take during the trip, plus an alcohol swab packet, plus a sharps disposal container or sealed plastic bottle for used needles. TSA permits all of this in carry-on with the prescription label visible, but it requires more pre-trip planning and more bag space.

7. Sharps disposal

Both formats produce sharps waste — Wegovy pens have a built-in retractable needle but the pen itself is still sharps-classified and should not go in regular trash. Vial-and-syringe users produce one syringe + needle per week. Both should be disposed of in an FDA-cleared sharps container, which can be ordered from any pharmacy or major drugstore for $5–10. Some compounded telehealth providers ship a small sharps container with the starter kit.

8. Refill cadence and shipping

Wegovy pen: typically dispensed monthly (4 single-use pens per box for the once-weekly schedule). Most commercial pharmacies dispense Wegovy in 30-day or 90-day supplies depending on the patient's insurance.

Compounded vial: the typical monthly vial contains enough drug for 4 weekly doses at the patient's current dose tier. Telehealth providers ship to the patient's home in temperature-controlled packaging via overnight or 2-day carriers. The vial concentration may change as the patient escalates dose, since the same vial volume can deliver more drug per dose at higher concentrations.

9. Dose escalation flexibility

Wegovy pen: the FDA-approved dose escalation is fixed: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, four weeks at each dose [1]. To skip a step or move slower, the prescriber must override the standard schedule, which insurance plans often resist. The pens themselves are dose-locked — a 0.5 mg pen cannot deliver 0.4 mg.

Compounded vial: dose escalation is set by the prescriber and patient together. Because the vial contains a full month of drug at a specific concentration, the patient can be instructed to increase by smaller increments (e.g., 0.25 → 0.35 → 0.5 → 0.65 mg) or to stretch the escalation schedule longer than the standard 4-week intervals. Patients sensitive to nausea often appreciate this flexibility, though slower escalation does delay the full therapeutic effect.

10. Cost (the big one)

Wegovy pen: cash list price approximately $1,349 per month. Insurance copays vary widely; many plans require prior authorization and step therapy, and the out-of-pocket cost after authorization typically ranges from $25 to $200/month for covered patients. See our insurance coverage audit for the per-insurer breakdown.

Compounded vial: cash market median is around $199/month at the 0.5 mg dose tier, with the floor near $99/month at our cheapest verified providers. See our GLP-1 pricing index and cheapest compounded semaglutide investigation for the live data. The compounded format is roughly 5–10× cheaper than the brand-name pen for an uninsured patient.

11. Quality verification

Wegovy pen: manufactured at FDA-inspected Novo Nordisk facilities with batch-level release testing, sterility validation, and FDA serialization tracking. Counterfeiting is rare and generally caught at the pharmacy distribution level.

Compounded vial: the quality of the actual product depends entirely on the compounding pharmacy. Some compounders are PCAB-accredited and follow USP <797> sterile compounding standards rigorously [3]. Others have received FDA warning letters for adulteration, salt-form sourcing, or inadequate sterility validation — see our FDA warning letter investigation for the documented patterns. Patients should verify the compounding pharmacy their telehealth provider uses against our pharmacy database before choosing a compounded provider.

12. The FDA shortage list timing risk

Compounded semaglutide is only legally permitted while brand-name semaglutide remains on the FDA drug shortage list. If the FDA removes semaglutide from the shortage list — as it did temporarily with tirzepatide in late 2024 before re-listing — every compounded semaglutide telehealth provider becomes legally restricted overnight. Compounded patients should know that this is a regulatory possibility, not a certainty, and that some providers prepare patients for the transition by stockpiling vials in advance of any expected FDA action. There is no equivalent shortage-list risk for Wegovy pens.

How to decide

The decision is rarely about which format is “better” in absolute terms — it's about which set of operational trade-offs fits your specific situation. A short decision tree:

• If you're insurance-covered with a copay below $200/month, take the Wegovy pen. The cost difference isn't worth the operational complexity of vial-and-syringe.
• If you're paying out of pocket and the $1,000/month cash gap matters, the compounded vial is almost certainly the right answer — but spend the time to verify your provider's pharmacy partner against our pharmacy database.
• If you have a history of dosing errors with self-administered medications, lean toward the pen. The compounded vial-and-syringe format requires reliable unit conversion math at every dose.
• If you need dose escalation flexibility (slow titration, micro-dosing, alternative schedules), the compounded vial allows this; the pen does not.
• If you travel frequently, the pen format is slightly more convenient, but both formats work fine with basic planning.

For a side-by-side cost calculation specific to your dose and insurance situation, use our savings calculator. For the live pricing across every compounded provider we track, see the price tracker.